|
1
|
DeSantis C, Siegel R, Bandi P and Jemal A:
Breast cancer statistics, 2011. CA Cancer J Clin. 61:409–418. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng
H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China,
2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
EBCTCG (Early Breast Cancer Trialists'
Collaborative Group), . McGale P, Taylor C, Correa C, Cutter D,
Duane F, Ewertz M, Gray R, Mannu G, Peto R, Whelan T, et al: Effect
of radiotherapy after mastectomy and axillary surgery on 10-year
recurrence and 20-year breast cancer mortality: Meta-analysis of
individual patient data for 8135 women in 22 randomised trials.
Lancet. 383:2127–2135. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Guo H, Ingolia NT, Weissman JS and Bartel
DP: Mammalian microRNAs predominantly act to decrease target mRNA
levels. Nature. 466:835–840. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Almeida MI, Reis RM and Calin GA: MicroRNA
history: Discovery, recent applications, and next frontiers. Mutat
Res. 717:1–8. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Farazi TA, Spitzer JI, Morozov P and
Tuschl T: miRNAs in human cancer. J Pathol. 223:102–115. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hemmatzadeh M, Mohammadi H, Jadidi-Niaragh
F, Asghari F and Yousefi M: The role of oncomirs in the
pathogenesis and treatment of breast cancer. Biomed Pharmacother.
78:129–139. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Shimono Y, Mukohyama J, Nakamura S and
Minami H: MicroRNA regulation of human breast cancer stem cells. J
Clin Med. 5:52015. View Article : Google Scholar
|
|
10
|
Fu Q, Du Y, Yang C, Zhang D, Zhang N, Liu
X, Cho WC and Yang Y: An oncogenic role of miR-592 in tumorigenesis
of human colorectal cancer by targeting Forkhead Box O3A (FoxO3A).
Expert Opin Ther Targets. 20:771–782. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Jia YY, Zhao JY, Li BL, Gao K, Song Y, Liu
MY, Yang XJ, Xue Y, Wen AD and Shi L: miR-592/WSB1/HIF-1α axis
inhibits glycolytic metabolism to decrease hepatocellular carcinoma
growth. Oncotarget. 7:35257–35269. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Li X, Zhang W, Zhou L, Yue D and Su X:
MicroRNA-592 targets DEK oncogene and suppresses cell growth in the
hepatocellular carcinoma cell line HepG2. Int J Clin Exp Pathol.
8:12455–12463. 2015.PubMed/NCBI
|
|
13
|
Li Z, Li B, Niu L and Ge L: miR-592
functions as a tumor suppressor in human non-small cell lung cancer
by targeting SOX9. Oncol Rep. 37:297–304. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Liu M, Zhi Q, Wang W, Zhang Q, Fang T and
Ma Q: Up-regulation of miR-592 correlates with tumor progression
and poor prognosis in patients with colorectal cancer. Biomed
Pharmacother. 69:214–220. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Liu Z, Wu R, Li G, Sun P, Xu Q and Liu Z:
MiR-592 inhibited cell proliferation of human colorectal cancer
cells by suppressing of CCND3 expression. Int J Clin Exp Med.
8:3490–3497. 2015.PubMed/NCBI
|
|
16
|
Lv Z, Rao P and Li W: MiR-592 represses
FOXO3 expression and promotes the proliferation of prostate cancer
cells. Int J Clin Exp Med. 8:15246–15253. 2015.PubMed/NCBI
|
|
17
|
Yang Y, Xing Y, Liang C, Hu L, Xu F and
Chen Y: Crucial microRNAs and genes of human primary breast cancer
explored by microRNA-mRNA integrated analysis. Tumour Biol.
36:5571–5579. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhang W and Li Y: miR-148a downregulates
the expression of transforming growth factor-β2 and SMAD2 in
gastric cancer. Int J Oncol. 48:1877–1885. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Xu H, Fei D, Zong S and Fan Z:
MicroRNA-154 inhibits growth and invasion of breast cancer cells
through targeting E2F5. Am J Transl Res. 8:2620–2630.
2016.PubMed/NCBI
|
|
20
|
Xia W, Zhou J, Luo H, Liu Y, Peng C, Zheng
W and Ma W: MicroRNA-32 promotes cell proliferation, migration and
suppresses apoptosis in breast cancer cells by targeting FBXW7.
Cancer Cell Int. 17:142017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kong LY, Xue M, Zhang QC and Su CF: In
vivo and in vitro effects of microRNA-27a on proliferation,
migration and invasion of breast cancer cells through targeting of
SFRP1 gene via Wnt/β-catenin signaling pathway. Oncotarget.
8:15507–15519. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Blobe GC, Schiemann WP and Lodish HF: Role
of transforming growth factor beta in human disease. N Engl J Med.
342:1350–1358. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Gordon KJ and Blobe GC: Role of
transforming growth factor-beta superfamily signaling pathways in
human disease. Biochim Biophys Acta. 1782:197–228. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhang Y, Alexander PB and Wang XF: TGF-β
family signaling in the control of cell proliferation and survival.
Cold Spring Harb Perspect Biol. 9:pii: a022145. 2017. View Article : Google Scholar
|
|
25
|
Lin RL and Zhao LJ: Mechanistic basis and
clinical relevance of the role of transforming growth factor-β in
cancer. Cancer Biol Med. 12:385–393. 2015.PubMed/NCBI
|
|
26
|
Zheng R, Wang J, Wu Q, Wang Z, Ou Y, Ma L,
Wang M, Wang J and Yang Y: Expression of ALDH1 and TGFβ2 in benign
and malignant breast tumors and their prognostic implications. Int
J Clin Exp Pathol. 7:4173–4183. 2014.PubMed/NCBI
|
|
27
|
Kim S, Lee J, Jeon M, Nam SJ and Lee JE:
Elevated TGF-β1 and -β2 expression accelerates the epithelial to
mesenchymal transition in triple-negative breast cancer cells.
Cytokine. 75:151–158. 2015. View Article : Google Scholar : PubMed/NCBI
|
